THRESHOLD-BASED INSULIN-PUMP THERAPY led to a reduction in nocturnal hypoglycemia among 121 patients, compared to a control group using standard insulin-pump therapy; the threshold-suspend feature did not increase glycatedhemoglobin values. (NEJM [published online June 2013])
TOP LINE RESULTS FOR CARDIOVASCULAR OUTCOMES OF ONGLYZA
OLDER DIABETIC ADULTS
OLDER DIABETIC ADULTS who experienced a hypoglycemic event had a 2-fold increased risk for developing dementia compared with those who did not, a prospective study found. (JAMA Int Med [published online June 2013])
HORMONE THERAPY USING CONJUGATED EQUINE ESTROGENS (CEE)
HORMONE THERAPY USING CONJUGATED EQUINE ESTROGENS (CEE) administered to postmenopausal women aged 50 to 55 years produced neither sustained benefit nor risk to cognitive function, but it is unknown what effects CEE may produce if administered during menopause. (JAMA Int Med [published online June 2013])
A REVIEW OF BARIATRIC SURGICAL PROCEDURES
A REVIEW OF BARIATRIC SURGICAL PROCEDURES suggested that surgery in patients with a BMI of 30 to 35 and diabetes led to greater short-term weight loss and glucose outcomes compared with nonsurgical options; however, evidence for long-term outcomes is insufficient. (JAMA [June 5, 2013] 309:2250)
TOP LINE RESULTS FOR CARDIOVASCULAR OUTCOMES OF ONGLYZA, a drug to treat adult patients with type 2 diabetes and either cardiovascular disease or multiple risk factors, were announced by AstraZeneca and Bristol-Myers Squibb. (news.bms.com/press-release/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-savortimi-53-cardiovas&t635072877317613330)